3SBio Inc (83B) - Total Liabilities

Latest as of June 2025: €4.89 Billion EUR ≈ $5.71 Billion USD

Based on the latest financial reports, 3SBio Inc (83B) has total liabilities worth €4.89 Billion EUR (≈ $5.71 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does 3SBio Inc generate cash to assess how effectively this company generates cash.

3SBio Inc - Total Liabilities Trend (2016–2024)

This chart illustrates how 3SBio Inc's total liabilities have evolved over time, based on quarterly financial data. Check 3SBio Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.

3SBio Inc Competitors by Total Liabilities

The table below lists competitors of 3SBio Inc ranked by their total liabilities.

Company Country Total Liabilities
Sandfire Resources Ltd
AU:SFR
Australia AU$1.09 Billion
Reece Ltd
AU:REH
Australia AU$3.58 Billion
Pharmaron Beijing Co Ltd
SHE:300759
China CN¥10.62 Billion
Lien Viet Post Joint Stock Commercial Bank
VN:LPB
Vietnam ₫472.91 Trillion
E Ink Holdings
TWO:8069
Taiwan NT$36.74 Billion
Zhejiang CFMoto Power Co Ltd
SHG:603129
China CN¥10.74 Billion
Ringkjoebing Landbobank A/S
CO:RILBA
Denmark Dkr74.74 Billion
Bank of Ayudhya Public Company Limited
F:NVAU
Germany €2.16 Trillion

Liability Composition Analysis (2016–2024)

This chart breaks down 3SBio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 3SBio Inc (83B) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.34 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.30 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.21 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how 3SBio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for 3SBio Inc (2016–2024)

The table below shows the annual total liabilities of 3SBio Inc from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 €6.18 Billion
≈ $7.22 Billion
-13.15%
2023-12-31 €7.11 Billion
≈ $8.31 Billion
+7.94%
2022-12-31 €6.59 Billion
≈ $7.70 Billion
+44.64%
2021-12-31 €4.55 Billion
≈ $5.33 Billion
-0.66%
2020-12-31 €4.58 Billion
≈ $5.36 Billion
+3.03%
2019-12-31 €4.45 Billion
≈ $5.20 Billion
-9.78%
2018-12-31 €4.93 Billion
≈ $5.77 Billion
-19.45%
2017-12-31 €6.12 Billion
≈ $7.16 Billion
+43.32%
2016-12-31 €4.27 Billion
≈ $4.99 Billion
--

About 3SBio Inc

F:83B Germany Biotechnology
Market Cap
$6.58 Billion
€5.63 Billion EUR
Market Cap Rank
#3257 Global
#611 in Germany
Share Price
€2.39
Change (1 day)
-2.05%
52-Week Range
€1.27 - €3.88
All Time High
€3.88
About

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER… Read more